GleamWall
中文EN

ATRA Atara Biotherapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1604464 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,404.0%
TTM net income YoY69.1%
TTM EPS YoY82.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-64.7%
Net margin-66.2%
FCF margin-53.5%
EBITDA margin-61.8%

Returns

ROE-8,768.3%
ROA-62.2%
ROIC (approx.)—
Asset turnover0.94x

Leverage & solvency

Liabilities / assets189.2%
Debt / equity—
Current ratio0.48x
Interest coverage-18.08x

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-12.2%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$120.77M$128.94M
R&D expense$37.45M$151.48M
SG&A expense$26.25M$39.89M
Operating income$35.86M-$83.44M
Interest expense$3.79M$4.62M
Pretax income$32.72M-$85.42M
Income tax$31,000-$12,000
Net income$32.69M-$85.40M
EBITDA$37.98M-$78.39M
EPS (basic)2.61-11.41
EPS (diluted)2.57-11.41
Weighted avg. shares (diluted)12.72M7.49M
Balance sheet
Cash & equivalents$8.48M$25.18M
Short-term investments$0$17.47M
Receivables$1.25M$1.48M
Inventory$0$10.65M
Current assets$12.21M$64.89M
PP&E, net$73,000$1.29M
Total assets$20.23M$109.10M
Current liabilities$14.92M$134.57M
Total liabilities$58.74M$206.38M
Shareholders' equity-$38.50M-$97.28M
Shares outstanding7.32M5.86M
Cash flow statement
Operating cash flow-$50.94M-$68.72M
Capital expenditure$0$246,000
Free cash flow-$50.94M-$68.96M
Investing cash flow$18.15M$8.62M
Financing cash flow$16.10M$59.28M
Depreciation & amortization$2.12M$5.05M
Stock-based compensation$9.75M$27.00M

Free plan shows the latest 2 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.